Drug Database
PT

PT-007

✓ Approved

Pediatrix Therapeutics · Unknown · Unknown

What is PT-007?

PT-007 is a unknown developed by Pediatrix Therapeutics. It is approved for therapeutic indications via unknown.

Drug Profile

CompanyPediatrix Therapeutics
Drug ClassUnknown
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Pediatrix Therapeutics

Therapeutic Indications

PT-007 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersHereditary haemochromatosis✓ Approved

Related Research Articles

PubMedJournal of cardiovascular electrophysiology2026-08-30

Sub-Acute Re-Elevated Pacing Thresholds After Atrial Leadless Pacemaker Implantation.

Wu Dongyan D, He Le L, Lu Fengmin F, Shao Ying Y et al.

The safety and efficacy of the atrial leadless pacemaker (A-LP) with helix fixation have been demonstrated. Usually, elevated acute thresholds decrease gradually and normalize within 24 h. Here, we report a case of subacute re-elevation of pacing thresholds after hospital discharge. An 80-year-old female with a history of bradycardia underwent A-LP implantation. At the time of the procedure, the final pacing threshold (PT) was measured at 4.0 V/0.4 ms. On post-procedural Day 1, the PT at 0.4 ms pulse width decreased to 1.0 V. On Day 4, the PT was 1.0 V/0.4 ms prior to the patient's discharge. However, on Day 5, she was readmitted to the hospital due to the loss of atrial capture at the maximum output available after an intravenous administration of 150 mg amiodarone for atrial flutter. Over 3 days of monitoring, atrial PT was higher than 6 V/1.5 ms. A traditional DDD pacemaker was implanted due to recurrent sinus asystole associated with dizziness. At the 1-month follow-up, the PT of atrial A-LP was 0.5 V/0.4 ms. Two months later, an ambulatory Holter confirmed the stable and normal atrial capture of the A-LP after lowering the base rate of the DDD pacemaker. At the 3-month follow-up, PT of the A-LP remained 0.5 V/0.4 ms. Sub-acute re-elevated PT of the A-LP during the perioperative period may persist for more than 1 week and then normalize within 1 month. If PT re-elevation is suspected to be related to peri-electrode inflammation, a conservative approach with continued monitoring of threshold changes may be considered.

PMID 42669180
Read full article →
PubMediScience2026-08-30

Comparative effectiveness of multiple interventions for Alzheimer's disease on ABC syndromes and QoL: A Bayesian network meta-analysis.

Gao Fujia F, Luo Guangxin G, Liu Bokuan B, Qiu Xu X et al.

Evidence comparing directly pharmacological and non-pharmacological treatments for Alzheimer's disease (AD) is scarce. The ABC symptoms-activities of daily living (ADLs) (A), behavioral and psychological symptoms (BPSs) (B), cognitive function (C), and quality of life (QoL)-are critical for diagnosing and assessing treatment effects in AD. This study aims to evaluate five interventions for AD: pharmacological therapy (PT), photobiomodulation (PBM), cognitive therapy (CT), exercise therapy (ET), and repetitive transcranial magnetic stimulation (rTMS) using a Bayesian network meta-analysis approach. Among 6,450 records screened, 91 randomized controlled trials (RCTs) involving 12,242 participants met the inclusion criteria. PBM and rTMS showed significant benefits for cognitive function in AD patients. PT and CT showed notable effectiveness in enhancing activities of daily living. For QoL, CT and ET were identified as more favorable outcomes. Collectively, each intervention exerts unique merits targeting ABC symptoms and QoL, implying combined pharmacological and non-pharmacological regimens could optimize therapeutic gains for AD management.

PMID 42668611
Read full article →
PubMedJournal of colloid and interface science2026-08-30

Metal-organic framework-coupled ZnIn2S4 for boosting photocatalytic hydrogen evolution.

Yu Tingting T, Ran Yiqing Y, Gong Picheng P, Ye Hui H et al.

Metal-organic frameworks (MOFs) have attracted tremendous interest in the photocatalytic hydrogen evolution reaction (HER). Nevertheless, their practical catalytic performance is limited by the rapid recombination of photogenerated charge carriers and sluggish interfacial reaction kinetics. Herein, a hierarchically structured UiO-66-NH2(Hf) / ZnIn2S4 (denoted UN-66/ZIS) heterostructure was rationally fabricated via a solvothermal strategy to simultaneously regulate charge separation efficiency and optimize interfacial catalytic kinetics. Benefiting from the intimate heterointerface and built-in electric field, the optimized UN-66/ZIS sample exhibits remarkably improved visible-light absorption capability and charge transport efficiency, achieving a photocatalytic hydrogen production of 6052 ± 206 μmol·g-1, which greatly outperforms pristine UN-66 and ZIS. More importantly, in-situ X-ray photoelectron spectroscopy combined with density functional theory calculations directly unveils the mechanism of interfacial charge redistribution and directional electron transfer responsible for the enhanced carrier separation efficiency, offering mechanistic insights into the improved catalytic activity. Furthermore, loading of Pt cocatalyst effectively accelerates the surface hydrogen evolution kinetics. The corresponding hydrogen evolution rate increases to 14,403 ± 287 μmol·g-1·h-1, approximately seven times that of the Pt-free heterostructure. This work proposes a synergistic strategy integrating heterojunction engineering and cocatalyst modulation to simultaneously optimize light harvesting, charge separation and surface reaction kinetics, which provides new guidelines for the rational design of high-performance MOF/sulfide photocatalysts toward solar hydrogen production.

PMID 42669254
Read full article →
PubMediScience2026-08-30

Integrating neural decoding, memristive materials, and adaptive control frameworks for next-generation hippocampal memory prosthetics.

Mo Fan F, Zhao Xiaoyu X, Xu Yuanhong Y, Tang Chengxuan C et al.

Memory prosthetics, closed-loop brain-computer interfaces that decode hippocampal activity and deliver adaptive stimulation, are transitioning from animal proof-of-concept to first-in-human trials. Realizing chronically implantable systems requires co-design of three materials-mediated subsystems whose structure-property-processing (SPP) relationships have been treated in isolation: biocompatible electrode interfaces, on-chip neuromorphic computation, and closed-loop control hardware. This review presents an integrated framework. We map neuroscientific findings (theta-phase tracking, theta-gamma coupling, sharp-wave ripple detection) onto engineering specifications for latency, sampling, and charge injection, and onto materials requirements for impedance, switching endurance, and chronic stability. We develop an SPP taxonomy of two dominant materials families: chronic electrode coatings (Pt-Ir, IrOx, PEDOT:PSS, carbon-based, MXene) and oxide memristive synapses (Al2O3/TiO2-x, SrTiO3, HfO2). We further distinguish established findings from emerging directions and flag where small-cohort clinical results have been over-generalized. This synthesis provides materials-design targets for next-generation memory-prosthetic hardware.

PMID 42668603
Read full article →
PubMedResearch and practice in thrombosis and haemostasis2026-08-30

Management and outcomes in patients with cryptogenic stroke and weakly positive antiphospholipid antibodies.

Gatti Macy L E MLE, Messé Steven R SR, Cuker Adam A

The risk of recurrent stroke and optimal antithrombotic strategy for cryptogenic stroke in patients with weakly positive antiphospholipid antibodies (aPLs) are uncertain. The aim of this study was to describe antithrombotic practice patterns and clinical outcomes, comparing patients with weakly positive aPLs with those with strongly positive aPLs. This retrospective cohort study included patients who received care in the University of Pennsylvania Health System between March 1, 2017, and December 31, 2023, with index cryptogenic stroke or transient ischemic attack, positive aPLs persisting for ≥12 weeks, and not on antithrombotic therapy prior to the index event. We evaluated antithrombotic therapy recommendations using univariate hypothesis testing and clinical outcomes including stroke recurrence rate and major bleeding events using survival analyses, comparing patients with weakly positive aPLs and those with strongly positive aPLs. We identified 47 patients who met eligibility criteria, 30 weakly positive and 17 strongly positive. Warfarin was recommended less often (P = .007) and antiplatelet agents more often (P = .03) to patients with weakly positive aPLs, compared with those with strongly positive aPLs. With a median follow-up of 32 months (IQR, 24-48 months), the incidence of recurrent ischemic stroke was 0.169 events/person-year in the strongly positive group and 0.045 events/person-year in the weakly positive group (hazard ratio, 3.93; 95% confidence intervals, 1.14-13.55; P = .03). Bleeding events were rare. Most patients with cryptogenic stroke and weakly positive aPLs received antiplatelet agents. Patients with weakly positive aPLs had a lower incidence of recurrent stroke compared with patients with strongly positive aPLs, despite less intensive antithrombotic therapy.

PMID 42668533
Read full article →
PubMedFoot & ankle orthopaedics2026-08-30

Association Between Hypothyroidism and Postoperative Complications Following Operative Ankle Fracture Fixation: A Retrospective Cohort Study.

Sari Deen B DB, Monteiro Shawn K SK, Khatri Nabeel A NA, Sanford Christopher C

Hypothyroidism has been associated with altered bone metabolism, impaired mineralization, and increased fracture risk, but its relationship with postoperative complications after operative ankle fracture fixation remains poorly defined. This study evaluated whether preexisting hypothyroidism is associated with increased complications following surgical treatment of ankle fractures. Adults undergoing operative ankle fracture fixation or related ankle fracture surgery in TriNetX were stratified by hypothyroidism diagnosed within 6 months before or on surgery vs no recorded hypothyroidism history. Propensity score matching was performed 1:1 using demographic factors, diagnosis-coded obesity/overweight, hemoglobin A1c, tobacco-related variables, diabetes, chronic kidney disease, cardiovascular disease, chronic obstructive pulmonary disease, peripheral vascular disease, and osteoporosis. No single primary outcome was designated; all 6 outcomes were assessed on an equal, exploratory basis at 3 months, 6 months, and 1 year. After matching, 10 406 patients per cohort were included in the 3- and 6-month analyses, and 10 407 per cohort were included at 1 year. With the numbers available, no significant difference could be detected for any 3-month outcome. At 6 months, nonunion/malunion (RR, 1.305; 95% CI, 1.065-1.600; RD P = .010) and hardware failure (RR, 1.302; 95% CI, 1.058-1.602; RD P = .013) were higher in hypothyroid patients. At 1 year, nonunion/malunion (RR, 1.407; 95% CI, 1.166-1.698; RD P < .001) and hardware failure (RR, 1.264; 95% CI, 1.065-1.500; RD P = .007) remained higher. Infection, hardware removal, wound dehiscence, and broad procedure-related complications were not significant at any time point. In this propensity-matched retrospective cohort study, preexisting hypothyroidism was associated with modest but statistically significant increases in delayed osseous and hardware-related complications after operative ankle fracture surgery (P < .05 for both outcomes at 6 months and 1 year). These findings should be interpreted as associative and warrant prospective validation. Level III, retrospective cohort study.

PMID 42668731
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about PT-007